UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mouse models of advanced spontaneous metastasis for experimental therapeutics

Nature reviews. Cancer, 2011-02, Vol.11 (2), p.135-141

2011

Volltextzugriff (PDF)

Meet Our Editor-in-Chief

Clinical cancer drugs, 2017-05, Vol.4 (1), p.1-1

Francia, Giulio

2017

Volltextzugriff (PDF)

Meet Our Editor-in-Chief

Clinical cancer drugs, 2016-10, Vol.3 (2), p.75-75

Francia, Giulio

2016

Volltextzugriff (PDF)

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

Gut, 2013-02, Vol.62 (2), p.259-271

2013

Volltextzugriff (PDF)

Thrombospondin 1, a Mediator of the Antiangiogenic Effects of Low-Dose Metronomic Chemotherapy

Proceedings of the National Academy of Sciences - PNAS, 2003-10, Vol.100 (22), p.12917-12922

2003

Volltextzugriff (PDF)

Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer

Cancer letters, 2017-12, Vol.411, p.35-43

2017

Volltextzugriff (PDF)

Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients

Clinical and experimental medicine, 2021-02, Vol.21 (1), p.149-159

2021

Volltextzugriff (PDF)

ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth

Cell death & disease, 2022-08, Vol.13 (8), p.687-687, Article 687

2022

Volltextzugriff (PDF)

Precision therapeutic targeting of human cancer cell motility

Nature communications, 2018-06, Vol.9 (1), p.2454-14, Article 2454

2018

Volltextzugriff (PDF)

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3386-3391

2006

Volltextzugriff (PDF)

Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice

PloS one, 2018-05, Vol.13 (5), p.e0196892

2018

Volltextzugriff (PDF)

Roles for Endothelin Receptor B and BCL2A1 in Spontaneous CNS Metastasis of Melanoma

Cancer research (Chicago, Ill.), 2012-10, Vol.72 (19), p.4909-4919

2012

Volltextzugriff (PDF)

Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy

Neoplasia (New York, N.Y.), 2010-11, Vol.12 (11), p.928-940

2010

Volltextzugriff (PDF)

Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1

The journal of clinical endocrinology and metabolism, 2013-09, Vol.98 (9), p.E1465-E1473

2013

Volltextzugriff (PDF)

Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

Neoplasia (New York, N.Y.), 2011, Vol.13 (1), p.40-48

2011

Volltextzugriff (PDF)

Tumor-Associated Fibroblasts as “Trojan Horse” Mediators of Resistance to Anti-VEGF Therapy

Cancer cell, 2009-01, Vol.15 (1), p.3-5

2009

Volltextzugriff (PDF)

Label-Free Raman Imaging to Monitor Breast Tumor Signatures

Technology in cancer research & treatment, 2017-08, Vol.16 (4), p.461-469

2017

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor-Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth

Cancer research (Chicago, Ill.), 2008-01, Vol.68 (2), p.521-529

2008

Volltextzugriff (PDF)

Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

Clinical cancer research, 2006-02, Vol.12 (3), p.904-916

2006

Volltextzugriff (PDF)

Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1

Neoplasia (New York, N.Y.), 2012-09, Vol.14 (9), p.833-IN11

2012

Volltextzugriff (PDF)

Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.680-689

2012

Volltextzugriff (PDF)

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis

Breast (Edinburgh), 2013-08, Vol.22, p.S57-S65

2013

Volltextzugriff (PDF)

Editorial

Clinical cancer drugs, 2020-11, Vol.7 (2), p.64-64

Francia, Giulio

2020

Volltextzugriff (PDF)

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens

Cancer research (Chicago, Ill.), 2004-06, Vol.64 (11), p.3994-4000

2004

Volltextzugriff (PDF)

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies

Cancer research (Chicago, Ill.), 2004-09, Vol.64 (18), p.6616-6625

2004

Volltextzugriff (PDF)

1 – 25 von 147

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(126)

Publikationsform

Sprache

Englisch
(141)
Italienisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Life Sciences & Biomedicine
(82)
Humans
(64)
Oncology
(44)
Animals
(40)
Mice
(36)
Female
(34)
Cell Line, Tumor
(28)
Male
(28)
Biological And Medical Sciences
(23)
Tumors
(23)
Medical Sciences
(20)
Cardiac & Cardiovascular Systems
(18)
Cardiovascular System & Cardiology
(18)
Antineoplastic Agents
(15)
Chemotherapy
(15)
Pharmacology. Drug Treatments
(15)
Breast Cancer
(14)
Cyclophosphamide - Administration & Dosage
(14)
Xenograft Model Antitumor Assays
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Cancer Research
(27)
Clinical Cancer Drugs
(9)
Europace
(7)
Molecular Cancer Therapeutics
(6)
Neoplasia
(6)
Clinical Cancer Research
(5)
Heart Rhythm
(5)
Journal Of Interventional Cardiac Electrophysiology
(5)
Biochemical Pharmacology
(3)
Cancers
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mouse models of advanced spontaneous metastasis for experimental therapeutics

Meet Our Editor-in-Chief

Meet Our Editor-in-Chief

Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models

Thrombospondin 1, a Mediator of the Antiangiogenic Effects of Low-Dose Metronomic Chemotherapy

Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer

Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients

ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth

Precision therapeutic targeting of human cancer cell motility

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice

Roles for Endothelin Receptor B and BCL2A1 in Spontaneous CNS Metastasis of Melanoma

Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy

Antiproliferative and Proapoptotic Activity of Sunitinib on Endothelial and Anaplastic Thyroid Cancer Cells via Inhibition of Akt and ERK1/2 Phosphorylation and by Down-Regulation of Cyclin-D1

Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

Tumor-Associated Fibroblasts as “Trojan Horse” Mediators of Resistance to Anti-VEGF Therapy

Label-Free Raman Imaging to Monitor Breast Tumor Signatures

Vascular Endothelial Growth Factor-Mediated Decrease in Plasma Soluble Vascular Endothelial Growth Factor Receptor-2 Levels as a Surrogate Biomarker for Tumor Growth

Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

Metronomic Ceramide Analogs Inhibit Angiogenesis in Pancreatic Cancer through Up-regulation of Caveolin-1 and Thrombospondin-1 and Down-regulation of Cyclin D1

Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis

Editorial

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies

Suchergebnisse filtern